A longitudinal study of morning, evening, and night light intensities and nocturnal sleep quality in a working population

2021 ◽  
pp. 1-11
Author(s):  
Lau Amdisen ◽  
Stine Daugaard ◽  
Jesper Medom Vestergaard ◽  
Anne Vested ◽  
Jens Peter Bonde ◽  
...  
BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e045678
Author(s):  
Marit Müller De Bortoli ◽  
Inger M. Oellingrath ◽  
Anne Kristin Moeller Fell ◽  
Alex Burdorf ◽  
Suzan J. W. Robroek

ObjectivesThe aim of this study is to assess (1) whether lifestyle risk factors are related to work ability and sick leave in a general working population over time, and (2) these associations within specific disease groups (ie, respiratory diseases, cardiovascular disease and diabetes, and mental illness).SettingTelemark county, in the south-eastern part of Norway.DesignLongitudinal study with 5 years follow-up.ParticipantsThe Telemark study is a longitudinal study of the general working population in Telemark county, Norway, aged 16 to 50 years at baseline in 2013 (n=7952) and after 5-year follow-up.Outcome measureSelf-reported information on work ability (moderate and poor) and sick leave (short-term and long-term) was assessed at baseline, and during a 5-year follow-up.ResultsObesity (OR=1.64, 95% CI: 1.32 to 2.05) and smoking (OR=1.62, 95% CI: 1.35 to 1.96) were associated with long-term sick leave and, less strongly, with short-term sick leave. An unhealthy diet (OR=1.57, 95% CI: 1.01 to 2.43), and smoking (OR=1.67, 95% CI: 1.24 to 2.25) were associated with poor work ability and, to a smaller extent, with moderate work ability. A higher lifestyle risk score was associated with both sick leave and reduced work ability. Only few associations were found between unhealthy lifestyle factors and sick leave or reduced work ability within disease groups.ConclusionLifestyle risk factors were associated with sick leave and reduced work ability. To evaluate these associations further, studies assessing the effect of lifestyle interventions on sick leave and work ability are needed.


2018 ◽  
Vol 35 (8) ◽  
pp. 1109-1117 ◽  
Author(s):  
Kwo-Chen Lee ◽  
Ya-Ling Hsieh ◽  
Pi-Chu Lin ◽  
Yun-Ping Lin

Background: Sleep disturbance commonly has a negative impact on the well-being of family caregivers (FCs) of terminally ill patients with cancer. The effect of sleep disturbance on FCs has not been explored through long-term follow-up studies in Taiwan. Objective: The purposes of this study were to (1) identify the trajectory of sleep quality of FCs of terminally ill patients with cancer in Taiwan and (2) examine the determinants of sleep disturbance through a longitudinal follow-up until patient death. Methods: A prospective, longitudinal study was conducted among 95 FCs of terminally ill patients with cancer. The FCs’ sleep quality was measured subjectively by using the Pittsburgh Sleep Quality Index and objectively by wearing a wrist actigraphy for 48 hours each month during the 6-month follow-up assessments. The trajectory and determinants of sleep quality were identified using a generalized estimation equation approach. Results: The FCs’ sleep quality significantly decreased as the patient’s death approached. Family caregivers who were women or older, had a relative with a longer survival period after diagnosis, reported higher levels of depression and fatigue, and provided lower levels of assistance to their relatives experienced more sleep disturbance. Conclusion: The sleep quality of Taiwanese FCs significantly deteriorated as the death of the terminally ill patients with cancer approached. Early detection of the FCs’ sleep disturbance, increasing their self-awareness of sleep problems, and providing nonpharmacological interventions and psychosocial support may be helpful for FCs to improve their quantity and quality of sleep.


2019 ◽  
Vol 64 ◽  
pp. S184
Author(s):  
P. Kalil Morelhão ◽  
R. Zambelli Pinto ◽  
C. Gobbi ◽  
M. Rodrigues Franco ◽  
C. Frange ◽  
...  

2019 ◽  
Vol 16 (3) ◽  
pp. 427-433 ◽  
Author(s):  
Lee Smith ◽  
Igor Grabovac ◽  
Nicola Veronese ◽  
Pinar Soysal ◽  
Ahmet Turan Isik ◽  
...  

2017 ◽  
Vol 40 ◽  
pp. e176-e177
Author(s):  
E.Y.Y. Lau ◽  
W.Y. Kung ◽  
H.C.C. Hui ◽  
J. Lam ◽  
Y.C. Lam ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Sylvie Droit-Volet ◽  
Natalia Martinelli ◽  
Johann Chevalère ◽  
Clément Belletier ◽  
Guillaume Dezecache ◽  
...  

The home confinement imposed on people to fight the COVID-19 pandemic interrupted the flow of time by disrupting daily life, making them feel that time was passing slowly. The aim of this longitudinal study was to evaluate the evolution over time of this subjective experience of time and its significant predictors (boredom, decreased happiness, life rhythm, and sleep quality). Twso samples of French participants were followed up: the first for several weeks during the first lockdown (April 2020) and then 1year later (April 2021; Study 1), and the second during the first lockdown (April 2020) and then 6months (November 2020) and 1year later (April 2021; Study 2). Our study shows that the French participants have the feeling that time has passed slowly since the beginning of the first lockdown and that it has not resumed its normal course. This is explained by a persistent feeling of boredom characteristic of a depressive state that has taken hold in the population. The findings therefore suggest that the repeated contexts of confinement did not contribute to re-establishing a normal perception of time, to which a subjective acceleration of time would have testified.


PLoS ONE ◽  
2021 ◽  
Vol 16 (7) ◽  
pp. e0255274
Author(s):  
Soutarou Taguchi ◽  
Hirofumi Koide ◽  
Hiroko Oiwa ◽  
Miku Hayashi ◽  
Kazuhiro Ogawa ◽  
...  

Objective To clarify whether antiparkinsonian drugs contribute to nocturnal sleep disturbances in patients with Parkinson’s disease (PD). Background Although the major antiparkinsonian drugs L-dopa and dopamine agonists (DAs) have been found to affect sleep, little is known about the effects of specific drugs on sleep in PD patients. Methods The study participants consisted of 112 PD patients (median age 72.5 years [inter-quartile range: IQR 65–79]; mean disease duration 8.44 years [standard deviation: 7.33]; median Hoehn and Yahr stage 3 [IQR 2–3.75]) taking one of three types of non-ergot extended-release DAs (rotigotine 32; pramipexole 44; ropinirole 36) with or without L-dopa (median daily total dosage of antiparkinsonian drugs 525.5 mg [IQR 376.25–658] levodopa equivalent dose [LED]). Participants were assessed using the PD Sleep Scale-2 (PDSS-2). Results For the whole PD patient cohort, the PDSS-2 sleep disturbance domain score and the scores for item 1 assessing sleep quality and item 8 assessing nocturia were positively correlated with daily total dosage of antiparkinsonian drugs and dosage of L-dopa, but not with the dosage of DAs. Sub-analysis according to DA treatment revealed that DA dosage was not correlated with item 1 or 8 score in any of the subgroups. The LED ratio of rotigotine to the total dosage of antiparkinsonian drugs was inversely correlated with the item 1 score. Conclusions These data suggest that antiparkinsonian drugs, in particular L-dopa, adversely affect nocturnal sleep in PD patients, especially in terms of sleep quality and nocturia. Thus, adjusting both the total dosage of antiparkinsonian drugs and the dose-ratio of L-dopa might be key actions for alleviating poor sleep quality in patients with PD. Among DAs, we found a clear positive correlation between the dose-ratio of rotigotine and sleep quality. Thus, partial L-dopa replacement with rotigotine could improve sleep quality in patients with PD.


Sign in / Sign up

Export Citation Format

Share Document